Paving the way to better care

A public-private international research collaboration aiming to personalise prevention and treatment of cardiovascular disease.


The challenge of cardiovascular disease

Cardiovascular disease (CVD) is the most common cause of death worldwide and has an incredibly large impact on people’s lives and wellbeing. The combination of an ageing population, unhealthy lifestyle, and increased numbers of risk factors, like hypertension, dyslipidemia, diabetes, and chronic kidney disease has led to a rise in the number of patients with CVD, reaching over 85 million in Europe alone.

Despite scientific advancements, the combination of risk factors linked to CVD and the presence of co-morbidities have made treatment difficult, making it urgent to address the complexity of CVD.

iCARE4CVD's vision is to work towards a future where CVD is better understood, more effectively treated, and less devastating for individuals and communities.

Number of people affected by CVD

> 500 million worldwide

Number of people that die from CVD

~ 17 million worldwide

Play Video
Our Approach

About iCARE4VD

iCARE4CVD is an international, public-private research project that brings together 33 academic and industry partners united in the pursuit of improving the health of patients with CVD. The project will run for 4.5 years, led by University of Maastricht and Novo Nordisk.

iCARE4CVD aims to improve four key areas of current CVD healthcare by:

Number of partners

33 leading international partners from civil society, academia, and industry

Amount of funding

22 million euros

The years it will run for

4.5 years

The project will achieve this by:

Collecting large amounts of patient cohorts...

covering patients of all CVD stages - from early risk to established heart failure

Generating a federated database...

to ensure private and confidential remote access to data on an individual level

Determining the value of biomarkers from different sources...

such as blood, imaging, digital wearables, to support early detection, monitoring, and treatment guidance for the entire spectrum of patients

Conducting in-depth qualitative research with patients and other stakeholders...

to build a motivational framework for self-care by patients and ensure their needs are incorporated into the outputs of the project

Developing artificial intelligence (AI)-based models to support diagnosis and predict risk and treatment responses...

to map the complete patient journey and response to interventions in CVD

Validating AI-based models prospectively towards precision medicine...

enabling the development of personalized care pathways

iCARE4CVD partners

iCARE4CVD brings together 33 leading international partners from civil society, academia and industry, and is lead by Maastricht University and global
healthcare company Novo Nordisk.

Deutsches Herzzentrum der Charité
University of Glasgow
Mondor Institute for Biomedical Research
Medizinische Universität Wien
University Medical Center Groningen
Uniklinik RWTH Aachen
Astra Zeneca
Scientific Institute for Health Economics and Health Systems Research
German Foundation for the Chronically Ill
Erasmus MC
Human Technopole
Mario Negri Pharmacological Research Institute
Maastricht University
French-Speaking Society of the Type 1 Diabetes Cohort
Leiden University Medical Center
Queen’s University Belfast
Swiss Institute Of Bioinformatics
Thomas More
University College Dublin
Get in touch with us

Have any questions? Send us a message.

Feel free to reach out to us using the form below. We value your feedback, questions, and any inquiries you might have. Our team is here to assist you and will respond as soon as possible. We look forward to hearing from you and starting a meaningful conversation.

Stay In the loop:
Subscribe to our newsletter

Subscribe to our newsletter to stay up to date with all the most recent information about iCARE4CVD.